Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record.

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Open access
Keilholz, Ulrich, Punt, Cornelis J.A., Gore, Martin, Kruit, Wim, Patel, Poulam, Lienard, Danielle, Thomas, Jose, Proebstle, Thomas M., Schmittel, Alexander, Schadendorf, Dirk, Velu, Thierry, Negrier, Sylvie, Kleeberg, Ulrich, Lehman, Frederic, Suciu, Stefan, Eggermont, Alexander M.M. · 2005 · Journal of Clinical Oncology

Abstract

Background: Based on phase II trial results, chemoimmunotherapy combinations have become the preferred treatment for patients with metastatic melanoma in many institutions. This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma. Patients and Methods: Patients with advanced metastatic melanoma were randomly assigned to receive dacarbazine 250 mg/m 2 and cisplatin 30 mg/m 2 on days 1 to 3 combined with interferon-alfa-2b 10 × 10 6 U/m 2 subcutaneously on days 1 through 5 without (arm A) or with (arm B) a high-dose intravenous decrescendo regimen of IL-2 on days 5 through 10 (18 × 10 6 U/m 2/6 hours, 18 × 10 6 U/m 2/12 hours, 18 × 10 6 U/m 2/24 hours, and 4.5 × 10 6 U/m 2 for 3 × 24 hours). Treatment cycles were repeated in the absence of disease progression every 28 days to a maximum of four cycles. Results: Three hundred sixty-three patients with advanced metastatic melanoma were accrued. The median survival was 9 months in both arms, with a 2-year survival rate of 12.9% and 17.6% in arms A and B, respectively (P = .32; hazard ratio, 0.90; 95% CI, 0.72 to 1.11). There was also no statistically significant difference regarding progression-free survival (median, 3.0 v 3.9 months) and response rate (22.8% v 20.8%). Conclusion: Despite its activity in melanoma as a single agent or in combination with interferon-alfa-2b, the chosen schedule of IL-2 added to the chemoimmunotherapy combination had no clinically relevant activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.03.202

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Keilholz, U., Punt, C. J. A., Gore, M., Kruit, W., Patel, P., Lienard, D., Thomas, J., Proebstle, T. M., Schmittel, A., Schadendorf, D., Velu, T., Negrier, S., Kleeberg, U., Lehman, F., Suciu, S., & Eggermont, A. M. M.
Venue
Journal of Clinical Oncology
Published
2005-09-20
Volume
23
Issue
27
Pages
6747-6755
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2123138938
Cited by
165
References
0
FWCI
7.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. https://app.cochat.ai/papers/10.1200/jco.2005.03.202
The paper
Keilholz, U., Punt, C. J. A., Gore, M., Kruit, W., Patel, P., Lienard, D., Thomas, J., Proebstle, T. M., Schmittel, A., Schadendorf, D., Velu, T., Negrier, S., Kleeberg, U., Lehman, F., Suciu, S., & Eggermont, A. M. M. (2005). Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.03.202

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.